-
2
-
-
44949119412
-
Recent trends in prostate cancer mortality show a continuous decrease in several countries
-
Bouchardy C, Fioretta G, Rapiti E etal. Recent trends in prostate cancer mortality show a continuous decrease in several countries. Int. J. Cancer 2008; 123: 421-429.
-
(2008)
Int. J. Cancer
, vol.123
, pp. 421-429
-
-
Bouchardy, C.1
Fioretta, G.2
Rapiti, E.3
-
3
-
-
0242692717
-
Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE)
-
CaPSURE.
-
Cooperberg MR, Lubeck DP, Mehta SS, Caroll PR, CaPSURE. Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J. Urol. 2003; 170: S21-25.
-
(2003)
J. Urol.
, vol.170
-
-
Cooperberg, M.R.1
Lubeck, D.P.2
Mehta, S.S.3
Caroll, P.R.4
-
5
-
-
14744299390
-
Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association
-
Cancer Registration Committee of the Japanese Urological Association.
-
Cancer Registration Committee of the Japanese Urological Association. Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association. Int. J. Urol. 2005; 12: 46-61.
-
(2005)
Int. J. Urol.
, vol.12
, pp. 46-61
-
-
-
6
-
-
6044231016
-
Characteristics of patients with prostate cancer who have initially been treated by hormone therapy in Japan: J-CaP surveillance
-
Akaza H, Usami M, Hinotsu S etal. Characteristics of patients with prostate cancer who have initially been treated by hormone therapy in Japan: J-CaP surveillance. Jpn. J. Clin. Oncol. 2004; 34: 329-336.
-
(2004)
Jpn. J. Clin. Oncol.
, vol.34
, pp. 329-336
-
-
Akaza, H.1
Usami, M.2
Hinotsu, S.3
-
7
-
-
41149163722
-
Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer
-
Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann. Intern. Med. 2008; 148: 435-448.
-
(2008)
Ann. Intern. Med.
, vol.148
, pp. 435-448
-
-
Wilt, T.J.1
MacDonald, R.2
Rutks, I.3
Shamliyan, T.A.4
Taylor, B.C.5
Kane, R.L.6
-
8
-
-
70349320376
-
Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy
-
Cooperberg MR, Hinotsu S, Namiki M etal. Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. J. Clin. Oncol. 2009; 27: 4306-4313.
-
(2009)
J. Clin. Oncol.
, vol.27
, pp. 4306-4313
-
-
Cooperberg, M.R.1
Hinotsu, S.2
Namiki, M.3
-
9
-
-
68149098902
-
Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival
-
Akaza H, Hinotsu S, Usami M etal. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer 2009; 115: 3437-3445.
-
(2009)
Cancer
, vol.115
, pp. 3437-3445
-
-
Akaza, H.1
Hinotsu, S.2
Usami, M.3
-
10
-
-
34250008691
-
Bicalutamide 80mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer: findings from a phase 3 randomized, double-blind, multicenter trial in Japanese patients
-
Usami M, Akaza H, Arai Y etal. Bicalutamide 80mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer: findings from a phase 3 randomized, double-blind, multicenter trial in Japanese patients. Prostate Cancer Prostatic Dis. 2007; 10: 194-201.
-
(2007)
Prostate Cancer Prostatic Dis.
, vol.10
, pp. 194-201
-
-
Usami, M.1
Akaza, H.2
Arai, Y.3
-
11
-
-
78650188152
-
Combined androgen blockade for prostate cancer: review of efficacy, safety and cost-effectiveness
-
Akaza H. Combined androgen blockade for prostate cancer: review of efficacy, safety and cost-effectiveness. Cancer Sci. 2011; 102: 51-56.
-
(2011)
Cancer Sci.
, vol.102
, pp. 51-56
-
-
Akaza, H.1
-
12
-
-
0002387316
-
Prostate
-
International Union Against Cancer: Urologic Tumors. Sobin LH, Wittekind CH (eds)., 5th edn. John Wiley & Sons, New York
-
International Union Against Cancer: Urologic Tumors. Prostate. In: Sobin LH, Wittekind CH (eds). TNM Classification of Malignant Tumours, 5th edn. John Wiley & Sons, New York, 1997; 170-173.
-
(1997)
TNM Classification of Malignant Tumours
, pp. 170-173
-
-
-
13
-
-
24144493035
-
The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostate carcinoma
-
ISUP Grading Committee.
-
Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL, ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostate carcinoma. Am. J. Surg. Pathol. 2005; 29: 1228-1242.
-
(2005)
Am. J. Surg. Pathol.
, vol.29
, pp. 1228-1242
-
-
Epstein, J.I.1
Allsbrook Jr, W.C.2
Amin, M.B.3
Egevad, L.L.4
-
14
-
-
0030069896
-
Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors
-
Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat. Med. 1996; 15: 361-387.
-
(1996)
Stat. Med.
, vol.15
, pp. 361-387
-
-
Harrell Jr, F.E.1
Lee, K.L.2
Mark, D.B.3
-
15
-
-
0015370976
-
Studies on prostate cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate
-
Huggins C, Hodges C. Studies on prostate cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J. Clin. 1972; 22: 232-240.
-
(1972)
CA Cancer J. Clin.
, vol.22
, pp. 232-240
-
-
Huggins, C.1
Hodges, C.2
-
16
-
-
0036290334
-
Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer?
-
Labrie F, Candas B, Gomez JL, Cusan L. Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer? Urology 2002; 60: 115-119.
-
(2002)
Urology
, vol.60
, pp. 115-119
-
-
Labrie, F.1
Candas, B.2
Gomez, J.L.3
Cusan, L.4
-
17
-
-
0035915453
-
Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study
-
Harlan LC, Potosky A, Gilliland FD etal. Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study. J. Natl. Cancer Inst. 2001; 93: 1864-1871.
-
(2001)
J. Natl. Cancer Inst.
, vol.93
, pp. 1864-1871
-
-
Harlan, L.C.1
Potosky, A.2
Gilliland, F.D.3
-
18
-
-
33746880261
-
Efficacy of primary hormonal therapy for localized or locally advanced prostate cancer: results of a 10-year follow-up
-
Akaza H, Homma Y, Usami M etal. Efficacy of primary hormonal therapy for localized or locally advanced prostate cancer: results of a 10-year follow-up. BJU Int. 2006; 98: 573-579.
-
(2006)
BJU Int.
, vol.98
, pp. 573-579
-
-
Akaza, H.1
Homma, Y.2
Usami, M.3
-
19
-
-
24044444279
-
Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer
-
Janoff DM, Peterson C, Mongoue-Tchokote S etal. Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer. BJU Int. 2005; 96: 503-507.
-
(2005)
BJU Int.
, vol.96
, pp. 503-507
-
-
Janoff, D.M.1
Peterson, C.2
Mongoue-Tchokote, S.3
-
20
-
-
67349131277
-
Prostate specific antigen half-time and prostate specific antigen doubling time as predictors of response to androgen deprivation therapy for metastatic prostate cancer
-
Park YH, Hwang IS, Jeong CW, Kim HH, Lee SE, Kwak C. Prostate specific antigen half-time and prostate specific antigen doubling time as predictors of response to androgen deprivation therapy for metastatic prostate cancer. J. Urol. 2009; 181: 2520-2524.
-
(2009)
J. Urol.
, vol.181
, pp. 2520-2524
-
-
Park, Y.H.1
Hwang, I.S.2
Jeong, C.W.3
Kim, H.H.4
Lee, S.E.5
Kwak, C.6
-
21
-
-
0034728828
-
Maximum androgen blockade in advanced prostate cancer: and overview of the randomized trials
-
Prostate Cancer Trialists' Collaborative Group
-
Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: and overview of the randomized trials. Lancet 2000; 355: 1491-1498.
-
(2000)
Lancet
, vol.355
, pp. 1491-1498
-
-
-
22
-
-
34248169161
-
Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline
-
Loblaw DA, Virgo KS, Nam R etal. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J. Clin. Oncol. 2007; 25: 1596-1605.
-
(2007)
J. Clin. Oncol.
, vol.25
, pp. 1596-1605
-
-
Loblaw, D.A.1
Virgo, K.S.2
Nam, R.3
-
23
-
-
84857946027
-
Fifth Joint Meeting of J-CaP and CaPSURE: advancing the global understanding of prostate cancer and its management
-
Akaza H, Carroll P, Cooperberg MR, Hinotsu S. Fifth Joint Meeting of J-CaP and CaPSURE: advancing the global understanding of prostate cancer and its management. Jpn. J. Clin. Oncol. 2012; 42: 226-236.
-
(2012)
Jpn. J. Clin. Oncol.
, vol.42
, pp. 226-236
-
-
Akaza, H.1
Carroll, P.2
Cooperberg, M.R.3
Hinotsu, S.4
|